What GAO Found The Food and Drug Administration (FDA) has developed a suite of strategic planning documentation to guide modernization of its information technology (IT) systems and support the agency’s IT strategic mission. FDA’s strategic plan suite identifies IT strategic goals and captures key upcoming agencywide modernization efforts.
FDA’s strategic plans fully address six of eight strategic planning leading practices. For example, the plan aligns to agency and department-wide missions, identifies performance measures for meeting agency IT goals, and defines roles and responsibilities for meeting the goals.
Comparison of Food and Drug Adminstration (FDA) Strategic Plan Contents Against Leading Strategic Planning Practices However, FDA has not fully documented ways to monitor mitigation of key challenges to achieve its IT strategic goals or identified links between its major IT investments and its strategic goals, consistent with leading practices.
FDA’s strategic plans fully address six of eight strategic planning leading practices. For example, the plan aligns to agency and department-wide missions, identifies performance measures for meeting agency IT goals, and defines roles and responsibilities for meeting the goals.
Comparison of Food and Drug Adminstration (FDA) Strategic Plan Contents Against Leading Strategic Planning Practices However, FDA has not fully documented ways to monitor mitigation of key challenges to achieve its IT strategic goals or identified links between its major IT investments and its strategic goals, consistent with leading practices.
By including these details, FDA will be able to anticipate and overcome key challenges and effectively implement its major IT investments in line with strategic goals. For the five large major IT investments selected by GAO for review, FDA fully addressed two and partially addressed one of three leading practices for performance measurement.
Specifically, FDA created performance metrics for each investment that aligned with IT strategic goals and used these metrics to track investment performance. However, FDA did not demonstrate use of these metrics in managing and improving investment performance for one of the five investments.